Amyotrophic Lateral Sclerosis News and Research

RSS

Scientists discover role of nucleocytoplasmic transport in specific forms of ALS and FTD

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two devastating adult-onset neurodegenerative disorders.

15 Feb 2016

Mayo Clinic researchers uncover clues to apraxia of speech

It may start with a simple word you can't pronounce. Your tongue and lips stumble, and gibberish comes out. Misspeaking might draw a chuckle from family and friends. But, then, it keeps happening. Progressively, more and more speech is lost. Some patients eventually become mute from primary progressive apraxia of speech, a disorder related to degenerative neurologic disease.

15 Feb 2016

New study lays foundation for future gene replacement therapies to treat ALS patients

Scientists have demonstrated for the first time that it is possible to specifically modify gene expression in diseased upper motor neurons, brain cells that break down in ALS.

1 Feb 2016

New treatment could stop progression of ALS

Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, for nearly two years in one type of mouse model used to study the disease - allowing the mice to approach their normal lifespan.

29 Jan 2016

Stem cell transplantation of neurotrophic factors shows promise in ALS

Mesenchymal stem cells cultured to secrete neurotrophic factors can be administered to patients with amyotrophic lateral sclerosis without lasting unwanted effects and may have clinical benefits, indicates a phase I/II safety analysis study.

19 Jan 2016

Researchers identify protein that could protect against toxic degeneration of cells in ALS

J. Gavin Daigle, a PhD candidate at the LSU Health New Orleans School of Graduate Studies, is the first author of a paper whose findings reveal another piece of the Amyotrophic Lateral Sclerosis (ALS) puzzle.

19 Jan 2016

Three new genetic associations identified for primary open angle glaucoma

Researchers from Massachusetts Eye and Ear/Harvard Medical School and Case Western Reserve University School of Medicine have led an international effort to identify three genetic associations that influence susceptibility to primary open angle glaucoma -- the most common form of adult onset glaucoma and the leading cause of irreversible blindness in the world.

12 Jan 2016

NIH-funded analysis identifies three genes that contribute to most common form of glaucoma

An analysis funded by the National Eye Institute (NEI), part of the National Institutes of Health, has identified three genes that contribute to the most common type of glaucoma. The study increases the total number of such genes to 15.

12 Jan 2016

Scientists pin down structure of neuronal protein clumps associated with ALS

To create treatments for a disease without any, scientists need to study and understand the driving forces behind the faulty biology. Today, researchers at the University of North Carolina School of Medicine announced the first-ever evidence-based description of the neuronal protein clumps thought to be important in Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, a fatal neurodegenerative condition.

29 Dec 2015

Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Research that leads to improved therapies for Alzheimer's disease (AD) patients is one goal of Boston University School of Medicine professor of pharmacology and neurology Benjamin Wolozin, MD, PhD. He was one of six researchers awarded a two-year, $500,000 award in Alzheimer's Disease Drug Discovery Research by the Edward N. & Della L. Thome Memorial Foundation.

22 Dec 2015

Aquinnah secures $5 million private equity investment from Takeda

Aquinnah Pharmaceuticals announced today that it has received a $5 Million investment from Takeda Pharmaceutical Company, Limited, in it's first private equity financing. The company has assembled a world-class team of drug developers and an exceptional Scientific Advisory Board in the fields of Amyotrophic Lateral Sclerosis (ALS), protein and RNA regulation, and neurodegenerative diseases.

21 Dec 2015

Pauses and reversals ‘not uncommon’ in ALS progression

Patients with amyotrophic lateral sclerosis often have periods of stable disease, with some even experiencing brief improvements, shows analysis of the PRO-ACT database.

18 Dec 2015

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Isis Pharmaceuticals, Inc. today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1 Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS).

11 Dec 2015

Scientists identify new jelly-like properties of essential proteins that lead to serious diseases

Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or 'aggregation', of misshaped proteins and lead to serious diseases.

31 Oct 2015

Findings could lead to new treatment for ALS, dementia

University of Toronto (U of T) researchers are proposing a new way of understanding Amyotrophic Lateral Sclerosis (ALS), the devastating and incurable neurological disease. Their findings, published today in the journal Neuron, could be a major milestone on the path to a treatment for both ALS and dementia.

30 Oct 2015

RUCDR Infinite Biologics awarded $6 million grant from NINDS

The National Institute of Neurological Disorders and Stroke has awarded a five-year grant worth up to $6,034,323 to RUCDR Infinite Biologics, a unit of Rutgers' Human Genetics Institute of New Jersey. RUCDR, which is located on Rutgers' Busch Campus in Piscataway, is the world's largest university-based biorepository.

20 Oct 2015

Genetic mutation linked to ALS, FTD prevents proteins from entering and exiting the cell's nucleus

Three teams of scientists supported by the National Institutes of Health showed that a genetic mutation linked to some forms of amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) may destroy neurons by disrupting the movement of materials in and out of the cell's nucleus, or command center where most of its DNA is stored.

19 Oct 2015

Role for endogenous retrovirus proposed in ALS pathogenesis

Expression of the human endogenous retrovirus-K is upregulated in some patients with sporadic amyotrophic lateral sclerosis and causes degeneration of motor neurons when overexpressed in mice, research shows.

9 Oct 2015

U of T study provides hope for treating ALS and FTD

It's the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), but until now scientists weren't sure how a specific gene caused these devastating diseases. Now researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.

6 Oct 2015

Study suggests link between human endogenous retroviral genes and ALS

Scientists at the National Institutes of Health discovered that reactivation of ancient viral genes embedded in the human genome may cause the destruction of neurons in some forms of amyotrophic lateral sclerosis (ALS).

1 Oct 2015